Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin

被引:40
作者
Wong, SSY
Ng, TK
Yam, WC
Tsang, DNC
Woo, PCY
Fung, SKS
Yuen, KY
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Div Infect Dis, Hong Kong, Hong Kong, Peoples R China
[2] Princess Margaret Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[4] Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1016/S0732-8893(99)00141-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Four cases of bacteremia caused by Staphylococcus aureus with heteroresistance to vancomycin (hetero-VRSA) were described. In at least two of these four mortalities, the cause of death was temporally related to the hetero-VRSA bacteremia. The vancomycin and teicoplanin MICs of the resistant subpopulations of these four hetero-VRSA were 8 and 24 mu g/ml, respectively. All isolates were producers of beta-lactamase, produced penicillin-binding protein PBP2a, and possessed the mecA gene accounting for methicillin resistance. Thickening of the peptidoglycan cell wall was observed by electron microscopy. When ampicillin was combined with vancomycin, in vitro synergism was detected using the checkerboard titration method (epsilon FIC = 0.13). The use of vancomycin plus ampicillin-sulbactam could be a viable option in treating severe hetero-VRSA infection in view of the higher affinity of ampicillin toward PBP2a. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 22 条
[1]  
[Anonymous], METH DIL ANT SUSC TE
[2]   INVITRO ANTIMICROBIAL ACTIVITY OF IMIPENEM IN COMBINATION WITH VANCOMYCIN OR TEICOPLANIN AGAINST STAPHYLOCOCCUS-AUREUS AND STAPHYLOCOCCUS-EPIDERMIDIS [J].
BARR, JG ;
SMYTH, ETM ;
HOGG, GM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (11) :804-809
[3]  
*CDC, 1997, MMWR-MORBID MORTAL W, V46, P813
[4]   Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications [J].
Chambers, HF .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) :781-+
[5]   Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [J].
Climo, MW ;
Patron, RL ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1747-1753
[6]   Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995 [J].
de Neeling, AJ ;
van Leeuwen, WJ ;
Schouls, LM ;
Schot, CS ;
van Veen-Rutgers, A ;
Beunders, AJ ;
Buiting, AGM ;
Hol, C ;
Ligtvoet, EEJ ;
Petit, PL ;
Sabbe, LJM ;
van Griethuysen, AJA ;
van Embden, JDA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :93-101
[7]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
[8]   Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area [J].
Geisel, R ;
Schmitz, FJ ;
Thomas, L ;
Berns, G ;
Zetsche, O ;
Ulrich, B ;
Fluit, AC ;
Labischinsky, H ;
Witte, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (06) :846-848
[9]   Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].
Hiramatsu, K ;
Aritaka, N ;
Hanaki, H ;
Kawasaki, S ;
Hosoda, Y ;
Hori, S ;
Fukuchi, Y ;
Kobayashi, I .
LANCET, 1997, 350 (9092) :1670-1673
[10]   Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].
Hiramatsu, K ;
Hanaki, H ;
Ino, T ;
Yabuta, K ;
Oguri, T ;
Tenover, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136